European CHMP recommends license extension of liraglutide (Saxenda) for treatment of obesitiy in adolescents
The proposed license extension is for use as an adjunct to a healthy nutrition and increased physical activity for weight management in adolescent patients from the age of >12 years with obesity and body weight above 60 kg.
Source:
European Medicines Agency